# US 6,730,483 B2 · Phagemid for antibody screening

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,483 B2
- Document ID: US6730483B2
- Status: Granted
- Kind: B2
- Application number: 10/117,057
- Filed: 2002-04-08
- Published: 2002-10-31
- Granted: 2004-05-04
- Earliest claimed: 1991-07-08
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Inventors: Frank Breitling; Melvyn Little; Stefan Dübel; Michael Braunagel; Iris Klewinghaus
- Web page: https://patentgrep.com/patent/US6730483B2

## CPC

- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 14/005: from viruses
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/40: against enzymes
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C12N 2795/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2795/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.

## Claims

### Claim 1

A phagemid comprising DNA encoding a polypeptide-coliphage pIII fusion protein, wherein said fusion protein comprises a polypeptide and a coliphage pIII polypeptide and wherein said coliphage pIII polypeptide comprises contiguous amino and carboxy domains of a coliphage pIII protein.

### Claim 2 (depends on 1)

A phagemid according to claim 1 wherein said polypeptide-coliphage pIII fusion protein contains a protease-sensitive region between the polypeptide and the coliphage pIII polypeptide.

### Claim 3 (depends on 1)

A phagemid according claim 1 wherein said phagemid further comprises expression control elements upstream of said DNA and further encodes at least one selectable marker.

### Claim 4 (depends on 1)

A phagemid according to claim 1 wherein said phagemid is packaged into viral particles.

### Claim 5 (depends on 1)

A process for the production of a phagemid according to claim 1, comprising the step of incorporating the DNA encoding said polypeptide-coliphage pIII fusion protein into a phagemid vector.

### Claim 6 (depends on 5)

The process according to claim 5 further comprising inserting a protease-sensitive site between the DNA encoding the polypeptide and the DNA encoding the coliphage pIII polypeptide.

### Claim 7 (depends on 1, 2, 3, 4)

A library of phagemids wherein said phagemids are as defined in any one of claims 1 or 2-4 and wherein said phagemid library contains a plurality of members encoding different polypeptides.

### Claim 8 (depends on 4)

A library of phagemids wherein said phagemids are packaged into viral particles according to claim 4 and wherein said packaged phagemid library contains a plurality of members encoding different polypeptides.

### Claim 9 (depends on 8)

A method of screening for polypeptides from a library according to claim 8, comprising exposing said library to a ligand, and selecting those packaged phagemids that bind to the light.

### Claim 10 (depends on 9)

A method according to claim 9 further comprising the production of a polypeptide identified following said screening of said library or a portion of said library.

### Claim 11

A method of presenting a polypeptide at a surface of a phagemid viral particle, comprising producing said phagemid viral particle, wherein said phagemid viral particle comprises a DNA sequence encoding said polypeptide fused to a DNA sequence encoding a coliphage pIII polypeptide comprising contiguous amino and carboxy domains of a coliphage pIII protein.
